Otsuka Pharmaceutical, VOYXACT, Sibeprenlimab-szsi, IgA Nephropathy, IgAN, VISIONARY Trial, Phase 3 Clinical Trial, Kidney Disease, Kidney Function, eGFR, Proteinuria,

PRINCETON, N.J., and TOKYO, Japan — October 22, 2026 Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co.,...